Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NexGen EBA Biomarkers in TB
NCT02371681Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2015
- Primary completion
- Sep 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of isoniazid, rifampicin, pyrazinamide, moxifloxacin, ethambutol in pulmonary tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2015; status: completed.
02
Drugs
isoniazidrifampicinpyrazinamidemoxifloxacinethambutol
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02371681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371681.